Abstract：
We report a case of a severe ear infection in a 35-year-old man treated with ixekizumab for psoriasis. Ixekizumab is a humanized monoclonal antibody that selectively prevents the interaction between interleukin 17 A and its receptor. Biologicals like ixekizumab are used to achieve symptom relief in autoimmune diseases including psoriasis. Unlike the mild upper respiratory tract infections usually described as side-effects of this treatment, we report a case of a patient who presented with a severe otitis media, complicated with a facial paresis and nasopharyngeal abscess. To the best of our knowledge, this is the first case presenting a severe, complicated ear infection as a possible side effect of ixekizumab. We conclude that when using ixekizumab, vigilance for upper airway infections is needed and if necessary, interruption of therapy should be considered. However, further research is needed to confirm this hypothesis.
摘要：
我们报告了一例严重耳部感染的病例，该病例为一名35岁的男性患者，使用ixekizumab治疗牛皮癣。Ixekizumab是一种人源化单克隆抗体，可选择性阻止白介素17A及其受体之间的相互作用。像ixekizumab这样的生物制剂用于在包括牛皮癣的自身免疫性疾病中实现症状缓解。与通常描述为这种治疗副作用的轻度上呼吸道感染不同，我们报告了一例严重中耳炎的患者，并发面部轻瘫和鼻咽脓肿。据我们所知,这是第一个严重的案例，复杂的耳朵感染可能是ixekizumab的副作用。我们得出结论，当使用ixekizumab时，需要警惕上呼吸道感染，如有必要，应考虑中断治疗。然而,需要进一步的研究来证实这一假设。
